This is a non-clinical, in vitro update with no financial or regulatory catalyst — no immediate trading signal. Monitor for future clinical trial initiation or partnership announcements to validate the intranasal delivery platform.
Price Chart
Executive Summary
Clearmind Medicine announced positive in vitro permeation results for its intranasal MEAI formulation, showing 97.35% cumulative permeation at 180 minutes, comparable to a conventional solution. The data confirms that enhanced nasal retention does not compromise drug transport, supporting continued preclinical development for alcohol use disorder and weight management. This is an early-stage, non-clinical update with no financial data or regulatory milestones — a routine pipeline progress report for a micro-cap biotech.
Key Facts
- Intranasal MEAI achieved 97.35% cumulative permeation at 180 minutes vs 98.34% for conventional formulation.
- Permeation study used Franz diffusion cells with cellulose membrane and simulated nasal electrolyte solution.
- Results build on prior ex vivo mucoadhesion data showing enhanced nasal retention.
- MEAI is being developed for alcohol use disorder, weight management, obesity, and metabolic conditions.
- Clearmind holds 19 patent families including 32 granted patents.
Financial Impact
No financial data provided; preclinical update with no revenue, costs, or deal value disclosed.
Risk Factors
- Preclinical data may not translate to clinical efficacy or regulatory approval.
- Micro-cap biotech with $2M market cap faces high dilution and going-concern risk.
- No timeline provided for IND filing or human trials.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-087761 |
| Document: ea0301522-6k_clearmind.htm | 0001213900-26-087761 |
| Document: 0001213900-26-087761-index-headers.html | 0001213900-26-087761 |
| Document: 0001213900-26-087761-index.html | 0001213900-26-087761 |
| Document: 0001213900-26-087761.txt | 0001213900-26-087761 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 9d ago | 6-K | $6.00 | awaiting T+60 | — | $6.12 (−2.02%) |
Oct 13, 2026 13d ago | 6-K | $6.23 | awaiting T+60 | — | $6.12 (−1.74%) |
Oct 8, 2026 18d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.25%) |
Oct 7, 2026 19d ago | 6-K | $6.60 | awaiting T+60 | — | $6.12 (−7.25%) |
Sep 23, 2026 4w ago | 6-K | $0.8500 | awaiting T+60 | — | $6.12 (+620.16%) |
Sep 23, 2026 4w ago | Press Release | $0.8500 | awaiting T+60 | — | $6.12 (+620.16%) |
Sep 17, 2026 5w ago | Press Release | $6.86 | awaiting T+60 | — | $6.12 (−10.82%) |
Sep 14, 2026 6w ago | 6-K | $0.9440 | awaiting T+60 | — | $6.12 (+548.45%) |
Sep 8, 2026 6w ago | 6-K | $1.03 | awaiting T+60 | — | $6.12 (+494.31%) |
Sep 4, 2026 7w ago | 6-K | $1.16 | awaiting T+60 | — | $6.12 (−427.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers